Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy

Class III beta-tubulin (TUBB3) expression is recognized as a predictive marker for chemosensitivity to cisplatin- and taxane-based chemotherapies in various malignancies. The aim of this study was to clarify the predictive value of TUBB3 expression for the anticancer effects of first-line cisplatin-...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-03, Vol.38 (3), p.1629-1635
Main Authors: Miyata, Yasuyoshi, Matsuo, Tomohiro, Nakamura, Yuichiro, Yasuda, Takuji, Ohba, Kojiro, Takehara, Kosuke, Sakai, Hideki
Format: Article
Language:English
Subjects:
Aged
Anticancer properties
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - biosynthesis
Bladder
Bladder cancer
Cancer
Cancer therapies
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cytoplasm
Drug Resistance, Neoplasm
Female
Hazard assessment
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Medical prognosis
Metastases
Middle Aged
Multivariate Analysis
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - statistics & numerical data
Paclitaxel
Paclitaxel - administration & dosage
Patients
Prognosis
Proportional Hazards Models
Survival
Taxanes
Tubulin
Tubulin - biosynthesis
Tumors
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - metabolism
Urinary tract
Urothelial cancer
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Class III beta-tubulin (TUBB3) expression is recognized as a predictive marker for chemosensitivity to cisplatin- and taxane-based chemotherapies in various malignancies. The aim of this study was to clarify the predictive value of TUBB3 expression for the anticancer effects of first-line cisplatin-based chemotherapy and second-line paclitaxel-based chemotherapy in patients with urothelial cancer (UC). We reviewed 116 patients with UC (90 with bladder cancer and 27 with upper urinary tract cancer) treated with first-line cisplatin-based chemotherapy. Among them, 42 patients received a paclitaxel-based regimen as second-line chemotherapy for advanced cisplatin-resistant UC. TUBB3 expression was evaluated using immunohistochemistry, and survival analyses were performed using Kaplan-Meier survival curves and multivariate Cox proportional hazard analysis. TUBB3 was mainly detected in the cytoplasm of cancer cells, and 64 patients (55.2%) were judged as having positive TUBB3 expression. TUBB3 expression was significantly associated with tumour grade (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12394